A Phase I, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0077 as a Single Agent in Patients with Locally Advanced or Metastatic PIK3CA-Mutant Solid Tumors and in Combination with Endocrine and Targeted Therapies in Patients with Locally Advanced or Metastatic PIK3CA Mutant Hormone-Receptor Positive Breast Cancer
||Male and Female Patients
|U.S. Govt. ID:
||Research Nurse Navigator: 212-342-5162 / firstname.lastname@example.org
The purpose of the study is to evaluate the safety and side effects of the study drug, GDC-0077. This study also looks for any anti-cancer activity of GDC-0077 alone in participants with locally advanced or metastatic breast cancer in postmenopausal women.
Melissa Accordino, MD
|Have you been diagnosed with breast cancer?